Corium International, Inc. (CORI) saw its loss widen to $11.04 million, or $0.42 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $10.48 million, or $0.47 a share.
Revenue during the quarter grew 5.50 percent to $7.34 million from $6.96 million in the previous year period. Gross margin for the quarter expanded 2052 basis points over the previous year period to 22.80 percent.
Operating loss for the quarter was $9.03 million, compared with an operating loss of $8.57 million in the previous year period.
"The second quarter was an especially productive one for Corium, culminating in the recent clinical success of our proprietary Corplex Donepezil product candidate," said Peter D. Staple, president and chief executive officer of Corium.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
